

Bronchial Asthma

- **CLINICAL CASE**
- **A 38-year-old female presented with a worsening shortness of breath, chest tightness, and coughing, especially in the previous 2 weeks.**
- **She described itchy, watery eyes, congestion and runny nose when around cats and also in the spring and fall.**

Bronchial Asthma

- **Q.1 One of the following treatment options was prescribed to relieve her allergic condition:**

a. Atropine.

b. Oral aminophylline.

c. Aggressive therapy with oral steroids for 5 days.

d. Salbutamol.

Bronchial Asthma

- **Q.2 Your answer to the last question was based on that this drug will provide the patient with the following advantage:**
 - a. Its anti-inflammatory effect will dramatically relieve her allergic conditions together with her bronchial asthma.***
 - b. It provides effective bronchodilating activity.***
 - c. It antagonizes the overactive parasympathetic tone***

BRONCHIAL ASTHMA

By Dr. Rania A. Abdel-Emam

ANTI-ASTHMATIC DRUGS

- **Bronchodilators**
- β 2-adrenergic agonists
- Anticholinergic drugs
- Methylxanthines
- **Antiinflammatory drugs :**
- Corticosteroids
- Cromolyn sodium
- Leukotriene antagonists
- Anti-IgE therapy

ANTI-INFLAMMATORY DRUGS

CORTICOSTEROIDS

Mechanism of action:

- **HOW DO THEY IMPROVE BRONCHIAL ASTHMA?**
- [Potent anti-inflammatory drugs] by inhibition of the formation of inflammatory mediators and suppression of acute and chronic inflammation in airways. This is achieved via:
 - 1- **inhibition of phospholipase A₂** leading to inhibition of synthesis of inflammatory mediators from arachidonic acid.
 - 2- **inhibition of COX₂** leading to inhibition of production of PGNs by inflammatory cells.

CORTICOSTEROIDS

- 3- **reduces the levels of circulating eosinophils, lymphocytes, basophils & monocytes** leading to decrease bronchial infiltration by chronic inflammatory cells.
- 4- **reduces the release of histamine** from mast cells leading to decrease capillary permeability, vasoconstriction and tissue edema.
- **Potentiate the bronchodilator action of the β_2 agonists.**

Uses of corticosteroids in treating bronchial asthma

According to the route of administration

• **INHALATION**

- **1st line prophylactic therapy**
- beclomethasone, triamcinolone, budesonide.
- ADRs:
 - 1- Hoarseness of voice.
(due to direct effect on vocal cords)
 - 2- Oropharyngeal candidiasis.
(prevented by rinsing mouth and throat after each use)

∞ **SYSTEMICALLY**

- ∞ **Acute exacerbations** (short course of oral prednisone for 5 days).
- ∞ **Status asthmaticus** (I.V. methylprednisolone every 6 hours until the attack subsides. Then continue on oral prednisone).
- ∞ **The dose is gradually tapered over 10-14 days.**


MAST CELL STABILIZERS

Cromolyn sodium and nedocromil

- Stabilization of mast cell on exposure to allergens preventing degranulation and release of histamine and broncho-constrictor chemical mediators.
- **They are not useful in managing an acute asthma attack but only as a prophylactic treatment.**
- Given by **inhalation**.
- Nedocromil more effective than cromolyn and approved for 12 years and older [cromolyn is approved for all ages]

Leukotriene antagonists

- Leukotrienes are biochemical mediators from arachidonic acid through the **5-lipoxygenase** pathway.



- **Zileuton:** (four times daily)


It is **5-lipoxygenase inhibitor** preventing formation of both LTB_4 and the cysteinyl leukotrienes (LTC_4 , LTD_4 , LTE_4).

HEPATOTOXICITY

∞ (twice daily) ∞ (once daily)

- **Zafirlukast & Montelukast:**

They are **blockers of leukotriene receptors**.
Prophylactic ttt, **Aspirin induced asthma.**




- Used as a **Prophylactic** treatment of mild asthma.
- They are of value as a **prophylaxis against aspirin-induced asthma** where aspirin inhibits cyclooxygenase pathway of arachidonic acid metabolism giving the upper hand to lipoxygenase activity which then will be suppressed by antileukotrienes.

Anti-IgE therapy

Omalizumab

- It is a recombinant monoclonal antibody targeted against **free IgE** (Anti-antibody).
- IgE bound to omalizumab cannot bind to IgE receptors on mast cells and basophils, preventing the allergic reaction at a very early step in the process.
- Used as a **prophylactic** treatment



MANAGEMENT OF ACUTE ASTHMA

Mild attacks

- Inhalation of a short acting β_2 -agonist (salbutamol)

Moderate attacks

- Inhaled short acting β_2 agonist continuously
- Early administration of systemic corticosteroids

Severe attacks and status asthmaticus

- Oxygen.
- β_2 agonist (salbutamol), Anticholinergics, Methylxanthines I.V.
- Corticosteroids I.V.
- Mechanical ventilation.

Long-term management

- Avoidance of exposure to triggering factors
- Treatment of upper respiratory tract infections (e.g Sinusitis).
- Anti-asthmatic drugs:
 - Long acting B2 agonists (inhaled)
 - Corticosteroids (inhaled)
 - Mast cell stabilizers
 - Leukotriene antagonists
 - Anti-IgE therapy
- Hyposensitization
- Psychotherapy & biofeedback

Bronchial Asthma

- **Q.3 ONE of the following treatment options was given to her as a maintenance treatment:**

a. Ipratropium.

b. Intravenous aminophylline.

c. Inhaled corticosteroid and long-acting beta agonist.

d. Inhaled salbutamol.

Bronchial Asthma

❖ **For avoidance of recurrence of the acute attack of bronchial asthma; one of the following drugs was properly administered:**

A- Isoprenaline.

B- Epinephrine.

C- Cromolyn sodium.

D- Ephedrine.

Bronchial Asthma

- **The drug you selected in the last question is administered through one of the following routes:**
 - A- Subcutaneously.
 - B- Intramuscularly.
 - C- By inhalation.
 - D- Orally.

